New Animal Drugs; Change of Sponsor; Tiamulin, 75017-75018 [05-24165]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 242 / Monday, December 19, 2005 / Rules and Regulations
may be seen in the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, between 9
a.m. and 4 p.m., Monday through
Friday.
Under section 512(c)(2)(F)(iii) of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360b(c)(2)(F)(iii)), these
approvals qualify for 3 years of
marketing exclusivity beginning
November 23, 2005. Exclusivity applies
only to the effectiveness claim for adult
Cylicocyclus radiatus and Petrovinema
poculatus for which new data were
required.
The agency has determined under 21
CFR 25.33(d)(1) that these actions are of
a type that do not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
List of Subjects in 21 CFR Part 520
Animal drugs.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 520 is amended as follows:
I
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
1. The authority citation for 21 CFR
part 520 continues to read as follows:
I
Authority: 21 U.S.C. 360b.
§ 520.1452
[Amended]
2. Section 520.1452 is amended in
paragraph (d)(2) as follows:
a. By removing ‘‘and C. nassatus;’’
and adding in its place ‘‘C. nassatus,
and C. radiatus;’’ and
b. By removing ‘‘and Gyalocephalus
capitatus;’’ and adding in its place
‘‘Gyalocephalus capitatus; and
Petrovinema poculatus;’’.
I
§ 520.1453
Dated: December 8, 2005.
Bernadette A. Dunham,
Deputy Director, Office of New Animal Drug
Evaluation, Center for Veterinary Medicine.
[FR Doc. 05–24166 Filed 12–16–05; 8:45 am]
17:05 Dec 16, 2005
Jkt 208001
List of Subjects
21 CFR Part 520
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 520 and 558
New Animal Drugs; Change of
Sponsor; Tiamulin
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
SUMMARY: The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect a
change of sponsor for four approved
new animal drug applications (NADAs)
for oral dosage forms and feed uses of
tiamulin from Boehringer Ingelheim
Vetmedica, Inc., to Novartis Animal
Health US, Inc.
DATES: This rule is effective December
19, 2005.
FOR FURTHER INFORMATION CONTACT:
David R. Newkirk, Center for Veterinary
Medicine (HFV–100), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–6967, email: david.newkirk@fda.gov.
SUPPLEMENTARY INFORMATION:
Boehringer Ingelheim Vetmedica, Inc.,
2621 North Belt Highway, St. Joseph,
MO 64506–2002, has informed FDA that
it has transferred ownership of, and all
rights and interest in, the following four
approved NADAs, to Novartis Animal
Health US, Inc., 3200 Northline Ave.,
suite 300, Greensboro, NC 27408:
NADA Number
Trade Name
134–644
DENAGARD (tiamulin)
Soluble Antibiotic
139–472
DENAGARD (tiamulin)
25% Premixes
140–916
DENAGARD (tiamulin)
Liquid Concentrate
DENAGARD (tiamulin)/
chlortetracycline
Accordingly, the agency is amending
the regulations in 21 CFR 520.2455,
520.2456, and 558.600 to reflect the
transfer of ownership and a current
format.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
PO 00000
Frm 00023
Fmt 4700
Animal drugs.
21 CFR Part 558
Animal drugs, Animal feeds.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR parts 520 and 558 are amended as
follows:
I
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
Final rule.
I
VerDate Aug<31>2005
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
BILLING CODE 4160–01–S
141–011
[Amended]
3. Section 520.1453 is amended in
paragraph (d)(2) as follows:
a. By removing ‘‘and C. nassatus;’’
and adding in its place ‘‘C. nassatus,
and C. radiatus;’’ and
b. By removing ‘‘and Gyalocephalus
capitatus;’’ and adding in its place
‘‘Gyalocephalus capitatus; and
Petrovinema poculatus;’’.
75017
Sfmt 4700
1. The authority citation for 21 CFR
part 520 continues to read as follows:
I
Authority: 21 U.S.C. 360b.
2. Revise § 520.2455 to read as
follows:
I
§ 520.2455
Tiamulin.
(a) Specifications. (1) Each ounce of
concentrate solution contains 3.64
grams (12.3 percent) tiamulin hydrogen
fumarate.
(2) Each gram of soluble powder
contains 450 milligrams (mg) tiamulin
hydrogen fumarate.
(b) Sponsors. See Nos. 058198 and
059130 in § 510.600(c) of this chapter.
(c) Related tolerances. See § 556.738
of this chapter.
(d) Special considerations. (1) Swine
being treated with tiamulin should not
have access to feeds containing
polyether ionophores (e.g., lasalocid,
monensin, narasin, salinomycin, or
semduramycin) as adverse reactions
may occur.
(2) Do not use in swine weighing over
250 pounds (lb).
(e) Conditions of use in swine—(1)
Amounts and indications for use.
Administer in drinking water for 5
consecutive days:
(i) 3.5 mg per (/) lb of body weight
daily for treatment of swine dysentery
associated with Brachyspira
hyodysenteriae susceptible to tiamulin.
(ii) 10.5 mg/lb of body weight daily
for treatment of swine pneumonia due
to Actinobacillus pleuropneumoniae
susceptible to tiamulin.
(2) Limitations. Withdraw medication
3 days before slaughter following
treatment at 3.5 mg/lb and 7 days before
slaughter following treatment at 10.5
mg/lb of body weight. Prepare fresh
medicated water daily. Use as only
source of drinking water.
E:\FR\FM\19DER1.SGM
19DER1
75018
Federal Register / Vol. 70, No. 242 / Monday, December 19, 2005 / Rules and Regulations
§ 520.2456
I
[Removed]
3. Remove § 520.2456.
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
4. The authority citation for 21 CFR
part 558 continues to read as follows:
I
Authority: 21 U.S.C. 360b, 371.
§ 558.600
[Amended]
5. Amend § 558.600 in paragraph (b)
and in the table in paragraphs (e)(1)(i)
through (e)(1)(iv) in the ‘‘Sponsor’’
column by removing ‘‘000010’’ and by
adding in its place ‘‘058198’’.
I
Dated: December 6, 2005.
Bernadette A. Dunham,
Deputy Director, Office of New Animal Drug
Evaluation, Center for Veterinary Medicine.
[FR Doc. 05–24165 Filed 12–16–05; 8:45 am]
BILLING CODE 4160–01–S
Astrid Szeto, Center for Biologics
Evaluation and Research (HFM–17),
Food and Drug Administration, 1401
Rockville Pike, Suite 200N, Rockville,
MD 20852–1448, 301–827–6210.
SUPPLEMENTARY INFORMATION:
I. Introduction
II. Background
A. History of the Review
B. Comments on the December 1985
Proposal
III. Categorization of Products—Final
Order
Food and Drug Administration
21 CFR Part 610
[Docket No. 1980N–0208]
Biological Products; Bacterial
Vaccines and Toxoids; Implementation
of Efficacy Review
Food and Drug Administration,
HHS.
ACTION:
FOR FURTHER INFORMATION CONTACT:
Table of Contents
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
Anthrax Vaccine Adsorbed (AVA). The
final order concerning AVA is
published elsewhere in this issue of the
Federal Register. FDA is classifying
these products as Category I (safe,
effective, and not misbranded), Category
II (unsafe, ineffective, or misbranded),
or Category IIIB (off the market pending
completion of studies permitting a
determination of effectiveness).
DATES: This rule is effective December
19, 2006. The final order on
categorization of products is effective
immediately.
IV. FDA’s Response to Additional Panel
Recommendations
A. Generic Order and Wording of
Labeling
B. Periodic Review of Product
Labeling
Final rule and final order.
The Food and Drug
Administration (FDA) proposed to
amend the biologics regulations and
proposed to classify the bacterial
vaccines and toxoids on the basis of
findings and recommendations of the
Panel on Review of Bacterial Vaccines
and Toxoids (the Panel) on December
13, 1985. The Panel reviewed the safety,
efficacy, and labeling of bacterial
vaccines and toxoids with standards of
potency, bacterial antitoxins, and
immune globulins. After the initial final
rule and final order was vacated by the
U.S. District Court for the District of
Columbia on October 27, 2004, FDA
published a new proposed rule and
proposed order on December 29, 2004
(69 FR 78281). The purpose of this final
rule and final order is to amend the
biologics regulations, issue a final order
in response to the report and
recommendations of the Panel; and,
respond to comments on the previously
published proposed rule and proposed
order submitted to the Division of
Dockets Management. This final rule
and final order does not address
SUMMARY:
VerDate Aug<31>2005
17:05 Dec 16, 2005
Jkt 208001
C. Improvement in the Reporting of
Adverse Reactions
D. Periodic Review of Product
Licenses
E. Compensation for Individuals
Suffering Injury From Vaccination
F. Public Support for Immunization
Programs
G. Assuring Adequate Supplies of
Bacterial Vaccines and Toxoids;
Establishment of a National Vaccine
Commission
H. Consistency of Efficacy Protocols
I. The Effect of Regulations Protecting
and Informing Human Study
Subjects on the Ability to Conduct
Clinical Trials
J. Standards for Determining the
Purity of Diphtheria and Tetanus
Toxoids
K. Immunogenic Superiority of
Adsorbed Toxoids Over Fluid
Toxoids
L. Laboratory Testing Systems for
Determining Potency of Tetanus
PO 00000
Frm 00024
Fmt 4700
Sfmt 4700
and Diphtheria Toxoids
M. Potency Testing of Diphtheria and
Tetanus Toxoids for Pediatric Use
N. Potency Requirements for Pertussis
Vaccine
O. Weight-Gain Test in Mice for
Pertussis Vaccine
P. Agglutination Test to Determine
Pertussis Vaccine Response in
Humans
Q. Warnings in Labeling for Pertussis
Vaccine
R. Field Testing of Fractionated
Pertussis Vaccines
S. Use of Same Seed Lot Strain in
Manufacturing Bacillus CalmetteGuerin (BCG) Vaccine
T. Development of an Improved
Cholera Vaccine
U. Plague Vaccine Immunization
Schedule
V. FDA’s Response to General Research
Recommendations
VI. What Comments Did We Receive?
A. FDA’s Consideration of Comments
on the Panel’s Report
B. Biological Products Review Process
C. Plague Vaccine
D. Miscellaneous Comments
VII. Amendment to the Regulations
VIII. Analysis of Impacts
A. Review Under Executive Order
12866, the Regulatory Flexibility
Act, and the Unfunded Mandates
Reform Act of 1995
B. Environmental Impact
C. Paperwork Reduction Act of 1995
D. Federalism
IX. References
I. Introduction
On December 13, 1985, FDA proposed
to amend the biologics regulations and
proposed to classify the bacterial
vaccines and toxoids on the bases of
findings and recommendations of the
Panel. The Panel reviewed the safety,
efficacy, and labeling of bacterial
vaccines and toxoids with standards of
potency, bacterial antitoxins, and
immune globulins. After reviewing the
Panel’s report and comments on the
proposal, FDA published a final rule
and final order on January 5, 2004 (69
FR 255). On October 27, 2004, the U.S.
District Court for the District of
Columbia vacated the January 5, 2004,
final rule and final order. On December
29, 2004, FDA published a withdrawal
of the January 5, 2004, final rule and
final order. Concurrently with the
withdrawal of the final rule and final
order, FDA published again a proposed
rule and proposed order (69 FR 78281)
to provide notice and to give interested
persons an opportunity to comment.
The purpose of this document is to:
(1) Categorize those bacterial vaccines
E:\FR\FM\19DER1.SGM
19DER1
]]>Agencies
[Federal Register Volume 70, Number 242 (Monday, December 19, 2005)]
[Rules and Regulations]
[Pages 75017-75018]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-24165]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 520 and 558
New Animal Drugs; Change of Sponsor; Tiamulin
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect a change of sponsor for four approved new
animal drug applications (NADAs) for oral dosage forms and feed uses of
tiamulin from Boehringer Ingelheim Vetmedica, Inc., to Novartis Animal
Health US, Inc.
DATES: This rule is effective December 19, 2005.
FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for
Veterinary Medicine (HFV-100), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail:
david.newkirk@fda.gov.
SUPPLEMENTARY INFORMATION: Boehringer Ingelheim Vetmedica, Inc., 2621
North Belt Highway, St. Joseph, MO 64506-2002, has informed FDA that it
has transferred ownership of, and all rights and interest in, the
following four approved NADAs, to Novartis Animal Health US, Inc., 3200
Northline Ave., suite 300, Greensboro, NC 27408:
------------------------------------------------------------------------
NADA Number Trade Name
------------------------------------------------------------------------
134-644 DENAGARD (tiamulin) Soluble Antibiotic
------------------------------------------------------------------------
139-472 DENAGARD (tiamulin) 25% Premixes
------------------------------------------------------------------------
140-916 DENAGARD (tiamulin) Liquid Concentrate
------------------------------------------------------------------------
141-011 DENAGARD (tiamulin)/chlortetracycline
------------------------------------------------------------------------
Accordingly, the agency is amending the regulations in 21 CFR
520.2455, 520.2456, and 558.600 to reflect the transfer of ownership
and a current format.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects
21 CFR Part 520
Animal drugs.
21 CFR Part 558
Animal drugs, Animal feeds.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR parts 520 and
558 are amended as follows:
PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS
0
1. The authority citation for 21 CFR part 520 continues to read as
follows:
Authority: 21 U.S.C. 360b.
0
2. Revise Sec. 520.2455 to read as follows:
Sec. 520.2455 Tiamulin.
(a) Specifications. (1) Each ounce of concentrate solution contains
3.64 grams (12.3 percent) tiamulin hydrogen fumarate.
(2) Each gram of soluble powder contains 450 milligrams (mg)
tiamulin hydrogen fumarate.
(b) Sponsors. See Nos. 058198 and 059130 in Sec. 510.600(c) of
this chapter.
(c) Related tolerances. See Sec. 556.738 of this chapter.
(d) Special considerations. (1) Swine being treated with tiamulin
should not have access to feeds containing polyether ionophores (e.g.,
lasalocid, monensin, narasin, salinomycin, or semduramycin) as adverse
reactions may occur.
(2) Do not use in swine weighing over 250 pounds (lb).
(e) Conditions of use in swine--(1) Amounts and indications for
use. Administer in drinking water for 5 consecutive days:
(i) 3.5 mg per (/) lb of body weight daily for treatment of swine
dysentery associated with Brachyspira hyodysenteriae susceptible to
tiamulin.
(ii) 10.5 mg/lb of body weight daily for treatment of swine
pneumonia due to Actinobacillus pleuropneumoniae susceptible to
tiamulin.
(2) Limitations. Withdraw medication 3 days before slaughter
following treatment at 3.5 mg/lb and 7 days before slaughter following
treatment at 10.5 mg/lb of body weight. Prepare fresh medicated water
daily. Use as only source of drinking water.
[[Page 75018]]
Sec. 520.2456 [Removed]
0
3. Remove Sec. 520.2456.
PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
0
4. The authority citation for 21 CFR part 558 continues to read as
follows:
Authority: 21 U.S.C. 360b, 371.
Sec. 558.600 [Amended]
0
5. Amend Sec. 558.600 in paragraph (b) and in the table in paragraphs
(e)(1)(i) through (e)(1)(iv) in the ``Sponsor'' column by removing
``000010'' and by adding in its place ``058198''.
Dated: December 6, 2005.
Bernadette A. Dunham,
Deputy Director, Office of New Animal Drug Evaluation, Center for
Veterinary Medicine.
[FR Doc. 05-24165 Filed 12-16-05; 8:45 am]
BILLING CODE 4160-01-S
